Geben Sie eine Aktie oder eine Kryptowährung in der Suchleiste an, um eine Zusammenfassung zu erhalten
RetinalGenix Technologies Inc
RTGNRetinalGeniX Technologies Inc., an ophthalmic research and development company, focuses on developing solutions to screen, monitor, diagnose, and treat ophthalmic, optical, and sight-threatening disorders. Its products include the Retinal Imaging Screening Device, a portable retinal imaging system providing a wide field of view without requiring pupil dilation; and RetinalCam, an in-home/remote location patient-activated monitoring and imaging device offering real-time communication and alerting system for physicians. It also develops RTG-2023 for the treatment of dry age-related macular degeneration; and RTG-2024 for the treatment of Alzheimer's syndrome dementia. The company was incorporated in 2017 and is based in Petaluma, California. RetinalGenix Technologies Inc. is a subsidiary of Sanovas Ophthalmology, LLC. Address: 1450 North Mcdowell Boulevard, Petaluma, CA, United States, 94954
Analytics
Zielpreis von Wall Street
–KGV
–Dividendenrendite
–Laufendes Jahr
Letztes Jahr
Laufendes Quartal
Letztes Quartal
Laufendes Jahr
Letztes Jahr
Laufendes Quartal
Letztes Quartal
Schlüsselzahlen RTGN
Dividenden-Analyse RTGN
Dividendenwachstum über 5 Jahre
–Kontinuierliches Wachstum
–Ausschüttungsquote 5-Jahres-Durchschnitt
–Verlauf der Dividende RTGN
Bewertung der Aktie RTGN
Finanzen RTGN
Ergebnisse | 2019 | Dynamik |